Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSoftcat Regulatory News (SCT)

Share Price Information for Softcat (SCT)

Share Price is delayed by 15 minutes
Get Live Data
1,813.00    35.00 (1.97%)
Bid:
1,811.00
Ask:
1,813.00
Spread: 2.00 (0.11%)
Market Cap: £3.56b
SCT Live PriceLast checked at - London Stock Exchange

Intraday Softcat Share Chart

Appointment of Non-Executive Director

22 Mar 2022 07:00

RNS Number : 5212F
Softcat PLC
22 March 2022
Β 

22 March 2022

Β 

Softcat plc

Β 

Appointment of Non-Executive Director

Β 

Β 

Softcat plc ("Softcat" or the "Company"), a leading UK provider of IT infrastructure technology and services, is pleased to announce the appointment of Lynne Weedall as an independent non-executive Director of the Company.

Β 

Lynne brings significant experience to add to the Board of Softcat through a number of prior senior positions in Human Resources. Previous senior executive positions include Group People & Culture Director of Selfridges Group, and Group Human Resources & Strategy Director of Carphone Warehouse.

Β 

Since leaving Selfridges, Lynne has taken on non-executive director roles at Dr. Martens plc, Stagecoach Group plc and Treatt plc. She is chair of the remuneration committee at Dr. Martens plc and Stagecoach Group plc and the senior independent director at Dr. Martens plc and Treatt plc. Previous non-executive roles include William Hill plc and Greene King plc.

Β 

It is intended that Lynne's appointment will become effective from 3 May 2022. She will serve as Chair of the Board's Remuneration Committee, taking over from Karen Slatford who will continue as senior independent Director and Chair of the Nomination Committee.

Β 

Commenting on the appointment, Martin Hellawell, non-executive Chairman of Softcat said:

Β 

"The Board has previously discussed the potential benefits of adding a further non-executive Director, if that person would add further significant value to the Board's effectiveness, skillset and expertise and would be a good fit. Lynne certainly meets all these requirements as well as rebalancing the workload of some of our other non-executive Directors. I am delighted that she has agreed to join our Board.

Β 

Her insights from her executive career together with the significant experience gained on the boards of listed companies will further strengthen our Board. All of us at Softcat look forward to working with her and taking advantage of her insights as we push ahead with our proven strategy for growth.

Β 

I would like to thank Karen Slatford for chairing the Remuneration Committee so professionally and effectively since her appointment in 2019 and look forward to continuing to work closely with her in her Board roles at Softcat."

Β 

Β 

For further information, please contact:

Softcat plc

Graeme Watt, Chief Executive Officer

+44 (0)1628 403 610

Graham Charlton, Chief Financial Officer

Media Enquiries ‐ FTI Consulting LLP

Ed Bridges/Matt Dixon

+44 (0)20 3727 1000

Β 

Β 

Β 

Other information

The following details are required to be disclosed under 9.6.13R of the Listing Rules of the Financial Conduct Authority in respect of other directorships held by Lynne Weedall in a publicly quoted company at any time in the previous five years:

Β 

Β· 11 January 2021 - current. Dr. Martens plc: senior independent Director and Chair, Remuneration Committee.

Β· 1 August 2020 - current. Stagecoach Group plc: Non-executive Director and Chair, Remuneration Committee.

Β· 6 April 2019 - current. Treatt plc: Senior Independent Director and Chair, Nominations Committee.

Β· 1 July 2019 - 22 April 2021. William Hill plc: Non-executive Director & Chair, Remuneration Committee.

Β· 11 October 2012 - 30 October 2019. Greene King plc: Non-executive Director and Chair, Remuneration Committee.

Β 

Β 

Governance considerations and consequent Board composition

The Nomination Committee of Softcat worked with an external search firm on this appointment. The search firm provided a list of highly experienced candidates for the role, which included Lynne Weedall and each candidate was reviewed or interviewed by the Committee. Lynne stood out as the best candidate to further enhance the Board.

Β 

Since January 2021, Lynne and Softcat non-executive Director Robyn Perriss have both served as independent non-executive Directors of Dr. Martens plc, a UK listed company. However, they are not involved in executive duties for Dr. Martens plc and each have a similar obligation to be independent for Dr. Martens plc as they do for Softcat. Consequently, the Board of Softcat does not consider that their position as independent non-executive Directors of the Company are adversely impacted by their roles on the board of Dr. Martens plc. The Board of Softcat is satisfied that they are both to be regarded as independent under the 2018 UK Corporate Governance Code.

Β 

Following Lynne Weedall's appointment, the composition of the Board will be:

Β 

Non-executive Directors:

Β· Martin Hellawell - Chair

Β· Karen Slatford - Chair of the Nomination Committee and senior independent Director

Β· Lynne Weedall - Chair of the Remuneration Committee

Β· Robyn Perriss - Chair of the Audit Committee

Β· Vin Murria - Designated Director for Workforce Engagement

Β 

Β 

Executive Directors:

Β· Graeme Watt - CEO

Β· Graham Charlton - CFO

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BOAPPUUAWUPPGBG
Date   Source Headline
10th Jun 20262:21 pmRNSHolding(s) in Company
9th Jun 20263:28 pmRNSDirector/PDMR Shareholding
1st Jun 20263:37 pmRNSAdmission to Trading
1st Jun 20263:32 pmRNSTotal Voting Rights
22nd May 20267:00 amRNSQ3 2026 Trading Update
8th May 20263:39 pmRNSDirector/PDMR Shareholding
7th May 20263:50 pmRNSHolding(s) in Company
6th May 202611:00 amRNSHolding(s) in Company
5th May 20262:00 pmRNSHolding(s) in Company
1st May 20269:42 amRNSTotal Voting Rights
1st May 20269:39 amRNSAdmission to Trading
30th Apr 202610:00 amRNSHolding(s) in Company
29th Apr 202612:39 pmRNSDirector/PDMR Shareholding
29th Apr 20269:25 amRNSHolding(s) in Company
27th Apr 202611:06 amRNSHolding(s) in Company
23rd Apr 20262:55 pmRNSDirector/PDMR Shareholding
14th Apr 20262:59 pmRNSHolding(s) in Company
13th Apr 20269:02 amRNSHolding(s) in Company
9th Apr 20264:05 pmRNSDirector/PDMR Shareholding
1st Apr 202612:26 pmRNSAdmission to Trading
1st Apr 202611:56 amRNSTotal Voting Rights
18th Mar 20267:00 amRNSHalf-year Report
11th Mar 202611:03 amRNSDirector/PDMR Shareholding
11th Mar 202611:03 amRNSDirector/PDMR Shareholding
2nd Mar 20269:51 amRNSTotal Voting Rights
27th Feb 20267:00 amRNSNotice of Results
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20265:44 pmRNSTransaction in Own Shares
12th Feb 20266:09 pmRNSTransaction in Own Shares
11th Feb 20265:32 pmRNSTransaction in Own Shares
10th Feb 20265:44 pmRNSTransaction in Own Shares
10th Feb 20262:32 pmRNSDirector/PDMR Shareholding
9th Feb 20265:52 pmRNSTransaction in Own Shares
6th Feb 20265:52 pmRNSTransaction in Own Shares
5th Feb 20265:49 pmRNSTransaction in Own Shares
4th Feb 20266:01 pmRNSTransaction in Own Shares
3rd Feb 20265:49 pmRNSTransaction in Own Shares
2nd Feb 20265:49 pmRNSTransaction in Own Shares
2nd Feb 20264:06 pmRNSTotal Voting Rights
30th Jan 20265:33 pmRNSTransaction in Own Shares
29th Jan 20265:47 pmRNSTransaction in Own Shares
28th Jan 20265:37 pmRNSTransaction in Own Shares
27th Jan 20265:26 pmRNSTransaction in Own Shares
26th Jan 20265:38 pmRNSTransaction in Own Shares
23rd Jan 20265:29 pmRNSTransaction in Own Shares
22nd Jan 20265:30 pmRNSTransaction in Own Shares
21st Jan 20265:12 pmRNSTransaction in Own Shares
20th Jan 20265:42 pmRNSTransaction in Own Shares
19th Jan 20265:33 pmRNSTransaction in Own Shares
16th Jan 20265:16 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.